Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Clesrovimab 105 mg	2,421
Overall Study	STARTED	Placebo	1,211
Overall Study	Treated	Clesrovimab 105 mg	2,411
Overall Study	Treated	Placebo	1,203
Overall Study	Safety Analysis Population	Clesrovimab 105 mg	2,409
Overall Study	Safety Analysis Population	Placebo	1,202
Overall Study	Participants Who Entered RSV Season 2	Clesrovimab 105 mg	1,017
Overall Study	Participants Who Entered RSV Season 2	Placebo	501
Overall Study	COMPLETED	Clesrovimab 105 mg	2,257
Overall Study	COMPLETED	Placebo	1,126
Overall Study	NOT COMPLETED	Clesrovimab 105 mg	164
Overall Study	NOT COMPLETED	Placebo	85

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04767373/flow